Fidaxomicin for the Treatment of <i>Clostridioides difficile</i> Infection in Adult Patients: An Update on Results from Randomized Controlled Trials
In recently updated international guidelines, fidaxomicin is preferentially recommended as first-line treatment over vancomycin both for the first episode of CDI and for rCDI, based on the results of different randomized controlled trials (RCTs). Although noninferiority was the rule in phase-3 RCTs...
Saved in:
Main Authors: | Daniele Roberto Giacobbe (Author), Antonio Vena (Author), Marco Falcone (Author), Francesco Menichetti (Author), Matteo Bassetti (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2022-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Fidaxomicin Use in the Pediatric Population with Clostridioides difficile
by: Oliver MB, et al.
Published: (2022) -
Real-World Budget Impact of Fidaxomicin versus Vancomycin or Metronidazole for In-Hospital Treatment of <i>Clostridioides difficile</i> Infection
by: Laura Whitney, et al.
Published: (2023) -
The Risk of <i>Clostridioides difficile</i> Recurrence after Initial Treatment with Vancomycin or Fidaxomicin Utilizing Cerner Health Facts
by: Ronald G. Hall, et al.
Published: (2022) -
Real-world effectiveness of fidaxomicin in patients at high risk of Clostridioides difficile recurrence
by: Benjamin Colwell, et al.
Published: (2024) -
Comparison of fidaxomicin to oral vancomycin for the treatment of Clostridioides difficile infection in hospitalized patients
by: A. Krishna Rao, et al.
Published: (2022)